19 / 30
Hellman, MD et al. Lancet 2016
Checkmate 012: 1L Nivolumab plus ipilimumab in NSCLC
PD-L1 expression and efficacy
of 1L Nivolumab in advanced
NSCLC
Carbone, DP et al. NEJM 2017
Checkmate 026: 1L Nivolumab in NSCLC
|
|
19 / 30
19 / 30
Hellman, MD et al. Lancet 2016
Checkmate 012: 1L Nivolumab plus ipilimumab in NSCLC
PD-L1 expression and efficacy
of 1L Nivolumab in advanced
NSCLC
Carbone, DP et al. NEJM 2017
Checkmate 026: 1L Nivolumab in NSCLC